March 27, 2020 -- Atum has granted commercial and academic laboratories free access to its Leap-In Transposase protein production platform for use in creating tools and resources to battle the COVID-19 pandemic.
The platform contains a variety of viral proteins, antibodies, interleukins, and related protein molecules that are being evaluated in COVID-19 clinical trials. It can also help with the rapid production of commercial-grade protein.
Laboratories can use the platform to develop diagnostic tools, vaccines, and protein-based therapies to help combat the COVID-19 pandemic. Atum is fully operational and currently processing rush orders, the company noted.